Looking for the Holy Grail-Drug Candidates for Glioblastoma Multiforme Chemotherapy

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2022 May 28

PMID 35625738

Authors

Beata Pajak

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the deadliest and the most heterogeneous brain cancer. The median survival time of GBM patients is approximately 8 to 15 months after initial diagnosis. GBM development is determined by numerous signaling pathways and is considered one of the most challenging and complicated-to-treat cancer types. Standard GBM therapy consist of surgery followed by radiotherapy or chemotherapy, and combined treatment. Current standard of care (SOC) does not offer a significant chance for GBM patients to combat cancer, and the selection of available drugs is limited. For almost 20 years, there has been only one drug, Temozolomide (TMZ), approved as a first-line GBM treatment. Due to the limited efficacy of TMZ and the high rate of resistant patients, the implementation of new chemotherapeutics is highly desired. However, due to the unique properties of GBM, many challenges still need to be overcome before reaching a 'breakthrough'. This review article describes the most recent compounds introduced into clinical trials as drug candidates for GBM chemotherapy.

Citing Articles

Immunotherapy against glioblastoma using backpack-activated neutrophils.

Fukuta T, Kumbhojkar N, Prakash S, Shaha S, Silva-Candal A, Park K Bioeng Transl Med. 2025; 10(1):e10712.

PMID: 39801750 PMC: 11711226. DOI: 10.1002/btm2.10712.

Development of a biocompatible 3D hydrogel scaffold using continuous liquid interface production for the delivery of cell therapies to treat recurrent glioblastoma.

Kass L, Thang M, Zhang Y, DeVane C, Logan J, Tessema A Bioeng Transl Med. 2024; 9(6):e10676.

PMID: 39545092 PMC: 11558199. DOI: 10.1002/btm2.10676.

Potent Biological Activity of Fluorinated Derivatives of 2-Deoxy-d-Glucose in a Glioblastoma Model.

Soltyka-Krajewska M, Ziemniak M, Zawadzka-Kazimierczuk A, Skrzypczyk P, Siwiak-Niedbalska E, Jaskiewicz A Biomedicines. 2024; 12(10).

PMID: 39457553 PMC: 11504489. DOI: 10.3390/biomedicines12102240.

Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.

Khagi S, Kotecha R, Gatson N, Jeyapalan S, Abdullah H, Avgeropoulos N Oncologist. 2024; 30(2).

PMID: 39401002 PMC: 11883162. DOI: 10.1093/oncolo/oyae227.

Role of scaffold proteins in the heterogeneity of glioblastoma.

Iyer V, Donahue J, Osman M Cell Commun Signal. 2024; 22(1):477.

PMID: 39375741 PMC: 11457365. DOI: 10.1186/s12964-024-01809-1.

References

Lee A . Fuzuloparib: First Approval. Drugs. 2021; 81(10):1221-1226. PMC: 8380563. DOI: 10.1007/s40265-021-01541-x. View

Tan A, Ashley D, Lopez G, Malinzak M, Friedman H, Khasraw M . Management of glioblastoma: State of the art and future directions. CA Cancer J Clin. 2020; 70(4):299-312. DOI: 10.3322/caac.21613. View

Mann B, Johnson J, Cohen M, Justice R, Pazdur R . FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007; 12(10):1247-52. DOI: 10.1634/theoncologist.12-10-1247. View

Sutendra G, Michelakis E . Pyruvate dehydrogenase kinase as a novel therapeutic target in oncology. Front Oncol. 2013; 3:38. PMC: 3590642. DOI: 10.3389/fonc.2013.00038. View

Vander Heiden M, Cantley L, Thompson C . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324(5930):1029-33. PMC: 2849637. DOI: 10.1126/science.1160809. View

Michelakis E, Webster L, Mackey J . Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008; 99(7):989-94. PMC: 2567082. DOI: 10.1038/sj.bjc.6604554. View

Carvalho B, Fernandes A, Almeida D, Sampaio L, Costa A, Caeiro C . Second-Line Chemotherapy in Recurrent Glioblastoma: A 2-Cohort Study. Oncol Res Treat. 2015; 38(7-8):348-54. DOI: 10.1159/000431236. View

Lyon K, Huang J . Bevacizumab as an adjuvant therapy for glioblastoma in elderly patients: the facts. Transl Cancer Res. 2018; 7(Suppl 7):S802-S805. PMC: 6202032. DOI: 10.21037/tcr.2018.08.19. View

Jin P, Madieh S, Augsburger L . The solution and solid state stability and excipient compatibility of parthenolide in feverfew. AAPS PharmSciTech. 2008; 8(4):E105. PMC: 2750358. DOI: 10.1208/pt0804105. View

10.

Sabanes Zariquiey F, da Souza J, Estrada-Tejedor R, Bronowska A . If You Cannot Win Them, Join Them: Understanding New Ways to Target STAT3 by Small Molecules. ACS Omega. 2019; 4(9):13913-13921. PMC: 6714540. DOI: 10.1021/acsomega.9b01601. View

11.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

12.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

13.

Peters K, Lipp E, Miller E, Herndon 2nd J, McSherry F, Desjardins A . Phase I/II trial of vorinostat, bevacizumab, and daily temozolomide for recurrent malignant gliomas. J Neurooncol. 2017; 137(2):349-356. DOI: 10.1007/s11060-017-2724-1. View

14.

Abdelmalak M, Lew A, Ramezani R, Shroads A, Coats B, Langaee T . Long-term safety of dichloroacetate in congenital lactic acidosis. Mol Genet Metab. 2013; 109(2):139-43. PMC: 3751427. DOI: 10.1016/j.ymgme.2013.03.019. View

15.

Palmieri D, Lockman P, Thomas F, Hua E, Herring J, Hargrave E . Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res. 2009; 15(19):6148-57. PMC: 7356672. DOI: 10.1158/1078-0432.CCR-09-1039. View

16.

Cohen M, Johnson J, Pazdur R . Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005; 11(19 Pt 1):6767-71. DOI: 10.1158/1078-0432.CCR-05-0722. View

17.

Singh N, Miner A, Hennis L, Mittal S . Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021; 4:17-43. PMC: 8319838. DOI: 10.20517/cdr.2020.79. View

18.

Han D, Yu T, Dong N, Wang B, Sun F, Jiang D . Napabucasin, a novel STAT3 inhibitor suppresses proliferation, invasion and stemness of glioblastoma cells. J Exp Clin Cancer Res. 2019; 38(1):289. PMC: 6612138. DOI: 10.1186/s13046-019-1289-6. View

19.

Verma A, Lam Y, Leung Y, Hu X, Chen X, Cheung E . Combined use of arginase and dichloroacetate exhibits anti-proliferative effects in triple negative breast cancer cells. J Pharm Pharmacol. 2018; 71(3):306-315. DOI: 10.1111/jphp.13033. View

20.

Prokhorova I, Pyaskovskaya O, Kolesnik D, Solyanik G . Influence of metformin, sodium dichloroacetate and their combination on the hematological and biochemical blood parameters of rats with gliomas C6. Exp Oncol. 2018; 40(3):205-210. View